Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS)
CNY 31.24
(-0.13%)
CNY 31.24
(-0.13%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 223.48 Million CNY | 112.25% |
| 2022 | 105.29 Million CNY | 425.87% |
| 2021 | 20.02 Million CNY | -49.98% |
| 2020 | 40.02 Million CNY | 752.62% |
| 2019 | 4.69 Million CNY | 0.0% |
| 2018 | - CNY | 0.0% |
| 2017 | - CNY | 0.0% |
| 2016 | - CNY | -100.0% |
| 2015 | 3.57 Million CNY | -85.23% |
| 2014 | 24.18 Million CNY | -39.55% |
| 2013 | 40 Million CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 164.05 Million CNY | -45.1% |
| 2024 Q1 | 203.65 Million CNY | -8.87% |
| 2024 Q2 | 298.79 Million CNY | 46.72% |
| 2023 Q2 | 131.07 Million CNY | 5.16% |
| 2023 FY | 223.48 Million CNY | 112.25% |
| 2023 Q3 | 175.13 Million CNY | 33.61% |
| 2023 Q1 | 124.64 Million CNY | 18.38% |
| 2023 Q4 | 223.48 Million CNY | 27.61% |
| 2022 Q2 | 120.34 Million CNY | 140.45% |
| 2022 Q1 | 50.05 Million CNY | 149.97% |
| 2022 FY | 105.29 Million CNY | 425.87% |
| 2022 Q4 | 105.29 Million CNY | -25.33% |
| 2022 Q3 | 141.01 Million CNY | 17.17% |
| 2021 FY | 20.02 Million CNY | -49.98% |
| 2021 Q4 | 20.02 Million CNY | -61.55% |
| 2021 Q1 | 40.02 Million CNY | 0.0% |
| 2021 Q2 | 45.61 Million CNY | 13.95% |
| 2021 Q3 | 52.07 Million CNY | 14.18% |
| 2020 Q2 | 40 Million CNY | 0.0% |
| 2020 FY | 40.02 Million CNY | 752.62% |
| 2020 Q3 | 40 Million CNY | 0.0% |
| 2020 Q4 | 40.02 Million CNY | 0.07% |
| 2020 Q1 | - CNY | -100.0% |
| 2019 Q1 | - CNY | 0.0% |
| 2019 FY | 4.69 Million CNY | 0.0% |
| 2019 Q4 | 4.69 Million CNY | 0.0% |
| 2018 FY | - CNY | 0.0% |
| 2017 FY | - CNY | 0.0% |
| 2016 Q2 | - CNY | 0.0% |
| 2016 Q1 | - CNY | -100.0% |
| 2016 FY | - CNY | -100.0% |
| 2015 Q4 | 3.57 Million CNY | 0.0% |
| 2015 Q1 | - CNY | 0.0% |
| 2015 FY | 3.57 Million CNY | -85.23% |
| 2014 FY | 24.18 Million CNY | -39.55% |
| 2013 FY | 40 Million CNY | 0.0% |